Little Green Pharma selected to supply France’s medical cannabis pilot program
MONTRÉAL, Jan. 27, 2021 (GLOBE NEWSWIRE) — Elixxer Ltd. (TSX-V: ELXR) (OTC-QB: ELIXF) (FRA: 2LQA) (“Elixxer” or the “company”) is pleased to share the latest achievements of its largest holding Little Green Pharma Ltd. (LGP). LGP has achieved the following major milestone validating our investment:
The French Agency for the Safety of Medicines and Health Products (ANSM) has selected Little Green Pharma as 1 of 4 companies that will supply France’s medical cannabis pilot program. Under the program, participants will be provided with free products to patients that enol in the trial. LGP will be a both a main & substitute supplier for CBD sublingual oils.Currently Elixxer holds 27.4M shares of LGP and as of January 27, 2021 the closing price was $0.64 per share on the ASX, click link: LGP Share PriceElixxer will update the investors via press release on further developments from its holdings.About Elixxer Ltd. (www.Elixxer.com)Elixxer is a Canadian public company listed on the TSX Venture Exchange (TSX-V: ELXR) and the US OTC-QB exchange (OTCQB: ELIXF).Through its partners, Elixxer presently has significant interests in Australia, Jamaica, Switzerland, Italy and Canada.For further information please contact: Info@elixxer.comCaution Regarding Press ReleasesNeither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Notice Regarding Forward Looking StatementsThis press release may contain forward-looking statements with respect to Elixxer and its operations, strategy, investments, financial performance and condition. These statements can generally be identified by use of forward-looking words such as “may”, “will”, “expect”, “estimate”, “anticipate”, “intends”, “believe” or “continue” or the negative thereof or similar variations. The actual results and performance of Elixxer could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition, government regulation and the factors described under “Risk Factors and Risk Management” in Elixxer’s most recent Management’s Discussion and Analysis filed on SEDAR (www.sedar.com). The cautionary statements qualify all forward-looking statements attributable to Elixxer and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this press release, and Elixxer has no obligation to update such statements, except to the extent required by applicable securities laws.